Biologic drugs, made from living organisms, are big moneymakers partly because they have little competition from “biosimilars.” It’s a very different story in Europe.
It’s a little-known secret that patients can get thousands of dollars directly from a drugmaker.
A probe by the Government Accountability Office cites breakdowns in the Food and Drug Administration program that approves drugs for rare diseases.
Over the past five months, the Trump administration has proposed a series of reforms to lower the cost of prescription drugs.
Drug pricing is a top issue in the run-up to the midterm elections.
Pharmaceutical companies like Purdue Pharma, maker of OxyContin, often win patents for incremental changes with debatable value. Now there’s a twist involving an opioid treatment.
As HHS decided to cut $1.6 billion in drug payments to hospitals, it weighed thousands of comments generated by a pharmaceutical-funded advocacy group.
Instead of waiting for congressional action, federal regulators are looking at a series of actions to spur competition and drive down the cost of medicines.
Several major drugmakers vow to contain drug prices, but similar pledges since the 1990s have not had much impact.
Dr. Mark McClellan joined Johnson & Johnson’s board of directors after leaving the FDA, but the connection often isn’t mentioned in research papers or public events.
President Donald Trump’s much-awaited speech about slashing drug costs was long on rhetoric but short on specifics that will reduce prices.
Research is just beginning on infants born with neonatal abstinence syndrome, and doctors are optimistic that normal development is possible. Monitoring the families and making sure parents are treated for addiction is key.
President Donald Trump’s upcoming speech on drug prices comes after months of public comments and debate about tackling the issue.
An abortion drug invented decades ago is being used to treat Cushing’s syndrome — and it’s bringing in tens of millions of dollars a year.
In an exclusive interview, FDA Commissioner Scott Gottlieb describes what he’s doing to spur competition and bring down drug prices.
The Trump administration rolled out a list of actions to attack drug prices, but most dance around the edges.
The FDA’s Scott Gottlieb says the agency is focused on the big picture, and he wants to know why pharma churns out drugs for some rare diseases but not for others.
Some of the nation’s most influential scientists recommend eight steps to lower drug prices. KHN takes the political temperature and tells you the chances of Congress acting on them.
The House and Senate want to reduce or eliminate federal tax credits for “orphan drugs” used to treat rare diseases, but patients are fighting against the plan.
Drugmakers, hospitals and lawmakers are taking sides in a showdown over a discount program that covers drug purchases at some hospitals.